Genetron Health Establishes Strategic Partnership with NeoGenomics to Drive Global Oncology Drug Research and Development
BEIJING, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has entered into a strategic partnership with NeoGenomics, Inc. (NASDAQ: NEO), a company that specializes in cancer genetic testing and information services.
Genetron Health and NeoGenomics, Inc. will partner globally to provide select harmonized clinical trials, global translational research for pharmaceutical groups and technology platform providers that need a China arm for global or China focused trials. Additionally, NeoGenomics will support Genetron Health on ex-China trials requiring US, APJ and/or EMEA based trials. This will include developing and operating clinical trials for both oncology drugs and their corresponding companion diagnostics (CDx) products.
The partnership will combine the two companies’ strengths to leverage a rich, diverse core technology platform and product pipeline that covers molecular detection, histopathologic diagnosis, multi-fluorescence immunohistochemistry, flow cytometry, immunoassays, in situ hybridization, and cell genetic mapping. Combined, the two will have 15 CAP-accredited and CLIA-certified laboratories, a collective team of hundreds of scientists from multidisciplinary backgrounds, and a seasoned clinical drug trial and pharmaceutical services team. These assets will enable business partners to synchronize global clinical drug trials and companion diagnostics development.
“As a world leading oncology laboratory solution provider, NeoGenomics has accumulated a wealth of clinical experience and capabilities around the world,” said Dr. Yun-Fu Hu, Chief Medical Officer of Genetron Health. “We are excited to work with NeoGenomics and look forward to providing cutting-edge, integrated solutions for both Chinese and international pharmaceutical companies. Together, we will work to synchronize global oncology drug development, in order to accelerate market approval for new drugs and benefit patients around the world.”
"We look forward to partnering with Genetron Health in China primarily due to their long-standing experience in oncology molecular diagnostics, their footprint in clinical trials there and their ability to work closely with global partners," said Gina Wallar, President, Pharma Services, NeoGenomics Inc. “The combination of NeoGenomics’ global pharma services and clinical trials expertise and Genetron Health’s experience adopting international healthcare products for the China market will enhance our overall drug R&D support capacity. This will enable NeoGenomics to better serve the needs of global drug R&D clinical trial projects. Genetron’s capabilities will be complementary to those in our new Suzhou, China facility.”
About Genetron Holdings Limited
Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo, Carlsbad and San Diego, California; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and CAP accredited laboratories in Rolle, Switzerland, and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia. For additional information about NeoGenomics, visit /.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of federal securities laws which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.
Investor Relations Contact
US:
Hoki Luk
Email:
Phone: +1 (408) 891-9255
Media Relations Contact
Yanrong Zhao
